Group 1 - The core point of the article is that Huatai Fund Management Co., Ltd. has reduced its stake in 3SBio Inc. by selling 1.7845 million shares at a price of HKD 26.4494 per share, totaling approximately HKD 47.199 million [1] - After the reduction, the latest number of shares held by Huatai is approximately 151 million, representing a holding percentage of 5.93% [1]

Group 1 - The core point of the article is that Huatai Fund Management Co., Ltd. has reduced its stake in 3SBio Inc. by selling 1.7845 million shares at a price of HKD 26.4494 per share, totaling approximately HKD 47.199 million [1] - After the reduction, the latest number of shares held by Huatai Fund is approximately 151 million, representing a holding percentage of 5.93% [1]

Group 1 - The proposed fund manager, Ma Lei, has been with Huatai-PineBridge Fund Management Co., Ltd. since July 2018, focusing on the electronics and communications sector [1] - From March 21, 2022, to August 7, 2023, Ma Lei served as the assistant fund manager for the Huatai-PineBridge CSI Chip Industry Index Enhanced Fund [1] - As of April 30, 2024, Ma Lei will officially take on the role of fund manager and currently manages a total of 16 funds [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 汇添富创业板交易型开放式指数证券投资基金（基金简称：汇添富创业板ETF；场内简称：创业板ETF 汇添富；基金代码：159247；以下简称"本基金"）已于2026年1月19日结束募集。根据《汇添富创业板 交易型开放式指数证券投资基金基金份额发售公告》的相关约定，本基金募集规模上限为20亿元人民币 （不包括募集期利息，下同）。截至2026年1月19日，本基金募集规模未超过20亿元，本基金管理人将 对所有的有效认购申请全部予以确认。 投资者可登录本公司网站（www.99fund.com）查询相关信息或拨打客户服务电话（400-888-9918）咨询 相关事宜。 汇添富基金高度重视投资者服务和投资者教育，特此提醒投资者需正确认知基金投资的风险和长期收 益，做理性的基金投资人，做明白的基金投资人，享受长期投资的快乐！ 特此公告。 汇添富基金管理股份有限公司 2026年1月21日 汇添富科技领先混合型证券投资基金基金合同生效公告 公告送出日期：2026年01月21日 1 公告基本信息 ■ 2 基金募集情况 ■ 注：1、按照有关法律规定，本基金合同生效前的律师费、会计师费、 ...

Core Viewpoint - The A-share market is experiencing fluctuations, particularly affecting the innovative drug sector, with the ETF Huatai Innovation Drug (589120) declining by 2.05% and facing a five-day losing streak, despite attracting over 7.9 million yuan in funds [1][3]. Group 1: Market Performance - The Huatai Innovation Drug ETF (589120) has seen a decline in its constituent stocks, with major players like I-Mab and Junshi Biosciences dropping over 3%, and others like BeiGene and Zai Lab falling more than 2% [3]. - The top ten constituent stocks of the ETF show a negative trend, with BeiGene-U down by 2.38% and Junshi Biosciences-U down by 3.42%, indicating a general downturn in the sector [3]. Group 2: Long-term Outlook - Despite the short-term market pressure, the long-term outlook for the innovative drug sector remains positive, with expectations of a clear beta market driven by liquidity recovery at the beginning of the year [4]. - The JPM conference highlighted the achievements of over 20 Chinese pharmaceutical companies, with projections for significant revenue growth in innovative drugs, such as a 25% increase for Heng Rui in 2026 [4]. Group 3: Business Development (BD) Trends - The BD activities in the sector are at a peak, with 17 transactions occurring since January, totaling approximately 10.15 billion USD in upfront payments, significantly exceeding market expectations [5]. - The ongoing trend of foreign companies expanding in China and the increasing flow of funds into the innovative drug sector suggest a favorable environment for growth and investment [5]. Group 4: Investment Strategy - The innovative drug sector is recommended for increased allocation, particularly in Hong Kong stocks, as the market is currently at a relative bottom, with potential for new historical highs [5]. - The ETF focuses on leading innovative drug companies, providing a high degree of exposure to the opportunities presented by the rise of Chinese innovative drugs [5].

本次分红对象为权益登记日，本基金注册登记人登记在册的本基金全体份额持有人。，权益登记日为1 月22日，现金红利发放日为1月26日。选择红利再投资的投资者，其红利将按2026年01月22日除息后的 基金份额净值折算成基金份额，并于2026年01月23日直接计入其基金账户，2026年01月26日起，投资者 可以查询红利再投资的基金份额，并于本基金的开放日办理赎回等业务。根据财政部、国家税务总局的 财税字〔2002〕128号《财政部、国家税务总局关于开放式证券投资基金有关税收问题的通知》，基金 向投资者分配的基金收益，暂免征收所得税。本基金本次分红免收分红手续费。选择红利再投资方式的 投资者其红利再投资所得的基金份额免收申购费用。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月20日发布《汇添富中证红利交易型开放式指数证券投资基金发起式联接基金收益分 配公告》。本次分红为本基金2026年度第1次分红。公告显示，本次分红的收益分配基准日为1月1日， 详细分红方案如下： ...

Group 1 - The core point of the news is that Lu Xi Chemical has seen a stock price increase of 5.03%, reaching 18.15 CNY per share, with a trading volume of 340 million CNY and a turnover rate of 1.00%, resulting in a total market capitalization of 34.563 billion CNY [1] - Lu Xi Chemical Group Co., Ltd. is located in the High-tech Industrial Development Zone of Liaocheng, Shandong, and was established on June 11, 1998. The company was listed on August 7, 1998, and its main business involves new chemical materials, basic chemicals, and other businesses [1] - The revenue composition of Lu Xi Chemical's main business includes: new chemical materials products at 66.07%, basic chemical products at 20.11%, fertilizer products at 12.06%, and other products at 1.76% [1] Group 2 - From the perspective of fund holdings, one fund under Huatai-PineBridge has a significant position in Lu Xi Chemical. The Huatai-PineBridge CSI National New Central Enterprise Shareholder Return ETF (560070) reduced its holdings by 66,300 shares, maintaining 820,700 shares, which accounts for 3.71% of the fund's net value, making it the third-largest holding [2] - The Huatai-PineBridge CSI National New Central Enterprise Shareholder Return ETF (560070) was established on May 24, 2023, with a latest scale of 321 million CNY. Year-to-date, it has a return of 0.14%, ranking 5040 out of 5579 in its category; over the past year, it has a return of 14.15%, ranking 3646 out of 4225; and since inception, it has a return of 20.81% [2] - The fund manager of the Huatai-PineBridge CSI National New Central Enterprise Shareholder Return ETF (560070) is Yan Yang, who has been in the position for 3 years and 192 days. The total asset scale of the fund is 7.293 billion CNY, with the best return during his tenure being 66.08% and the worst being -18.27% [3]

Group 1 - The core point of the article is that Huatai Fund Management Co., Ltd. has increased its stake in Sangfor Technologies (01530.HK) by purchasing 1,492,500 shares at an average price of HKD 28.1794 per share, totaling approximately HKD 42.058 million [1][2] - Following this transaction, Huatai Fund's total shareholding in Sangfor Technologies has risen to 152,745,500 shares, which represents an increase in ownership from 5.96% to 6.02% [1][2]

Core Viewpoint - The personal pension fund list in China has expanded, with 7 new products added, bringing the total to 309 funds by the end of last year [4][6]. Group 1: Fund Expansion - The latest list of personal pension funds includes 309 products, an increase of 7 from the end of the third quarter last year [4][6]. - The newly added funds consist of various types, including ordinary index funds, enhanced index funds, stable target pension funds, and target date funds [4][5]. Group 2: Fund Performance and Scale - The personal pension funds have seen significant performance and scale growth, with an average net value growth rate of 17.54% for 279 funds that have been established for over a year [8]. - As of the end of the third quarter of 2025, the total scale of personal pension funds reached 15.107 billion yuan, marking a 65.32% increase from the end of 2024 [8]. Group 3: Industry Insights - Public funds are recognized as pioneers in the personal pension business and play a crucial role in the personal pension ecosystem, with diverse product offerings and increasing long-term investment value [9].

公告送出日期：2026年01月17日 投资者可以通过拨打本公司客服热线（400-888-9918）或登录本公司网站（www.99fund.com）获取相关 信息。 汇添富基金高度重视投资者服务和投资者教育，特此提醒投资者需正确认知基金投资的风险和长期收 益，做理性的基金投资人，做明白的基金投资人，享受长期投资的快乐！ 特此公告。 汇添富基金管理股份有限公司 1 公告基本信息 ■ 注：1、自2026年01月19日起（含2026年01月19日），汇添富90天短债A暂停直销渠道的大额申购、大 额转换转入、大额定期定额投资业务，单日单个基金账户单笔或多笔累计申购、转换转入、定期定额投 资的金额不应超过5000000人民币元（含5000000人民币元）。当单日某基金账户单笔或多笔累计申购、 转换转入、定期定额投资该份额的金额超过5000000人民币元，本公司将部分或全部拒绝。本基金汇添 富90天短债A恢复直销渠道的大额申购、大额转换转入、大额定期定额投资业务的具体时间将另行公 告。 2、汇添富90天短债A仍暂停办理代销渠道的大额申购、大额转换转入、大额定期定额投资业务。该份 额其他业务仍照常办理。详见本公司于2022年 ...